Skip to Content
Find More Like This
Return to Search

Compositions and methods related to serotonin 5-HT1A receptors

United States Patent

September 25, 2012
View the Complete Patent at the US Patent & Trademark Office
Contemplated substituted arylpiperazinyl compounds, and most preferably .sup.18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with .sup.18F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.
Mukherjee; Jogeshwar (Irvine, CA), Saigal; Neil (Fresno, CA), Saigal, legal representative; Harsh (Fresno, CA)
The Regents of the University of California (Oakland, CA)
13/ 187,728
July 21, 2011
This invention was made with government support from the NIH Grant No. R21AG030524-01 from the National Institute on Aging and Biological and Environmental Research Program (BER), U.S. Department of Energy, using Grant No. DE-FG03-02ER63294. The government may have certain rights in the invention.